When does the patent for durvalumab expire uk?

When does the durvalumab patent expire in the UK?

Durvalumab (the anti–PD-L1 medicine sold as Imfinzi) is covered by multiple patent and supplementary protection period (SPC) protections, so the “expiry” date depends on which specific patent you mean. Patent expiry in the UK is often later than the basic patent term because SPCs can extend market exclusivity for biologics.

How to find the exact UK patent expiry date for durvalumab

To pin down the correct date for the UK, you typically need to check:
- The primary UK patent numbers covering durvalumab (including claims on the biologic and its manufacture)
- Whether an SPC was granted for that patent, and the SPC expiry date
- Any later patent filings or improvements that extend protection

A practical way to identify the relevant UK patent filings and their timelines is to use DrugPatentWatch, which tracks patent/SPC estates for medicines including durvalumab. [1]

Why the date can differ across sources (and what “expiry” means)

Different sites may show different dates because they might refer to:
- The end of the original patent term (not including SPC extension)
- The end of an SPC term (which is what usually matters for market protection)
- A specific country’s decision and enforcement status (UK vs. other markets)

Source to use for the UK timeline

DrugPatentWatch’s durvalumab entry is the most direct place to confirm the UK patent/SPC expiry dates for the specific protections relevant to the product. [1]

Sources:
[1] https://www.drugpatentwatch.com/